Funding high-risk, high-reward studies could lead to the development of novel approaches in ground-breaking research, but this funding is difficult to secure. The San Antonio Life Sciences Institute supports exactly this type of research that could have a translational impact on the $37 billion healthcare and bioscience industry in our city and beyond and lead to extramural funding.
Two collaborative teams comprised of researchers from both The University of Texas at San Antonio (UTSA) and UT Health San Antonio were each awarded SALSI Innovation Challenge Grants for $100,000 to study novel approaches to substance abuse and its prevention.
Can Astrocytes Lead to Better Drugs for Treating Addiction?
James Lechleiter, professor in the Department of Cell Systems and Anatomy in the Joe R. & Teresa Lozano Long School of Medicine at UT Health San Antonio and Matthew Wanat, an assistant professor of biology and behavioral physiologist at UTSA, are looking at how astrocytes could be targeted to help reduce a person’s cocaine use. Astrocytes are star-shaped glial cells that regulate the transmission of electrical impulses within the brain.
“Astrocytes play a critical role in the duration of the cell-to-cell electrical signals in the brain,” Lechleiter explained. Recent data in our lab suggest there are drugs that make astrocytes function better, which we hope will uncover a completely different means of treating addiction—with drugs that change how astrocytes function during cocaine’s effects on signaling.
“Our goal is to find a preclinical way to test a drug in mice to see if it reduces their self-administration of cocaine and really get at the mechanism of why it’s working,” Lechleiter said. “It’s going after the problem differently since we know that astrocytes play a huge role in addictive behavior—it’s a new way to look for drugs that can treat addiction.”
“There is no FDA-approved treatment for cocaine addiction, so is important to identify new potential targets to reduce cocaine intake,” Wanat said. The team is looking at a novel means to treat cocaine addiction and is leveraging Lechleiter’s work both at UT Health San Antonio and as co-founder of Astrocyte Pharmaceuticals.
“Abused drugs can change how the brain works, so the goal is to either prevent or reverse these changes,” Wanat said. “Jim’s research shows that astrocytes can be targeted to reduce brain damage from stroke and traumatic brain injury. My lab studies the role of the neurotransmitter dopamine in guiding behavioral actions. Together, our collaboration is the perfect marriage of different types of expertise that hopefully will identify new targets for treating drug addiction.”
What is the Neural Impact of Opioids and FDA-Approved Treatments on Pregnant Women?
Daniel Lodge, associate professor of Pharmacology in the Long School of Medicine at UT Health San Antonio and Jenny Hsieh, Ph.D., Semmes Foundation Chair in Cell Biology and director of the UTSA Brain Health Consortium are examining how to model addiction-related brain dysfunction using organoids. Organoids are brain cells that possess certain features of a human brain in the first trimester of fetal development, allowing researchers to explore how neurons grow and function.
One demographic not studied when modeling addiction-related brain dysfunction is pregnant women, according to Lodge. “Opioid use in pregnancy has increased dramatically, paralleling the epidemic observed across the U.S.,” he said. Lodge studies dopamine neuron function and its relevance to psychiatric disorders and opioid use disorders.
Lodge explained there are treatments for opioid use disorders like methadone, but researchers do not know what their effects are on pregnant women. “The goals for our research are twofold: look at the consequences of both opioids and of FDA-approved treatments on developing fetal brain tissue,” Lodge added.
Using cerebral organoids gives the team the ability to look at neural development while controlling for outside influences such as socio-economic factors. Hsieh works on in vitro models of cell development.
“Brain organoids mimic natural brain tissue in a dish,” Hsieh said. “We know that babies born from moms using them have neurological problems, so we can directly test the opioids on the brain cells in a dish and see what they do to fetal brain development.”
The combination of Hsieh’s expertise in stem cell biology and the developing brain and Lodge’s research on drug addiction pathways offers a unique opportunity to address the impact of opioids and FDA-approved treatments on pregnant women.
“Our partnership is synergistic and utilizes our unique expertise in these different areas to address the effects of drugs, especially during the development of the brain,” Hsieh said.
Texas State Senator José Menéndez (D-San Antonio District 26) who serves on the Senate Committee of Higher Education, advocated for the legislation that created the San Antonio Life Sciences Institute in 2003. Senator Menéndez is committed to research and teaching excellence in the biosciences at San Antonio’s two leading higher education institutions which not only impacts his district, but the entire state.
“Every day we can see the impact from the opioid epidemic on families and employers across Texas,” State Senator José Menéndez said. “Together with others in the Bexar County delegation, I have advocated for funding of the San Antonio Life Sciences Institute to support research excellence at our two leading higher education public institutions. I’m proud to learn that scientists at UT Health San Antonio and UTSA continue to collaborate in pursuit of innovative approaches to discovering the underlying causes for substance abuse with the hope that eventually it will lead to non-addictive treatments for pain management.”